GlucoTrack, Inc. - Common Stock (GCTK)
0.1374
-0.0065 (-4.52%)
NASDAQ · Last Trade: Jun 6th, 12:59 AM EDT
Detailed Quote
Previous Close | 0.1439 |
---|---|
Open | 0.1439 |
Bid | 0.1360 |
Ask | 0.1395 |
Day's Range | 0.1351 - 0.1459 |
52 Week Range | 0.1261 - 62.60 |
Volume | 2,074,563 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 7,804,275 |
Chart
About GlucoTrack, Inc. - Common Stock (GCTK)
GlucoTrack, Inc. is a healthcare technology company focused on the development of innovative non-invasive glucose monitoring solutions for individuals with diabetes. The company leverages advanced sensing technologies to create devices that enable users to track their blood glucose levels without the need for traditional fingerstick methods. GlucoTrack aims to improve the quality of life for diabetic patients by providing them with more convenient and accessible ways to manage their condition, while also enabling healthcare providers to better monitor patient health. Through its commitment to research and development, GlucoTrack seeks to contribute to more effective diabetes management and enhance overall patient outcomes. Read More
News & Press Releases

By Glucotrack, Inc. · Via GlobeNewswire · June 4, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · May 29, 2025
Glucotrack will host a virtual webinar discussing its Continuous Blood Glucose Monitor (CBGM) innovation on May 29 at 11 am ET.
Via TheNewswire.com · May 29, 2025

Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology
By Glucotrack, Inc. · Via GlobeNewswire · May 28, 2025
Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology
By Glucotrack, Inc. · Via GlobeNewswire · May 20, 2025
DETROIT, MICHIGAN - May 14, 2025 ( NEWMEDIAWIRE ) - Among the more challenging chronic conditions, diabetes represents both a social and economic burden, particularly for insulin-dependent cases . According to the National Diabetes Statistics Report, 38.4 million people of all ages - or 11.6% of the U.S. population – had diabetes. Of this, 1.7 million adults aged 20 years or older – or 5.7% of all U.S. adults with diagnosed diabetes – reported having the type 1 variant and using insulin.
Via TheNewswire.com · May 14, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · May 14, 2025
Long-term clinical evaluation represents key advancement following successful first-in-human study
By Glucotrack, Inc. · Via GlobeNewswire · May 13, 2025
Via Benzinga · May 5, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · May 5, 2025
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via Chartmill · April 30, 2025
Via Benzinga · April 30, 2025
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · April 30, 2025
Via Benzinga · April 30, 2025
The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today.
Via Chartmill · April 29, 2025
Via Benzinga · April 29, 2025
Continuous Blood Glucose Monitor will be integrated with automated insulin delivery system for major EU diabetes study
By Glucotrack, Inc. · Via GlobeNewswire · April 16, 2025
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data
By Glucotrack, Inc. · Via GlobeNewswire · April 3, 2025
Via Benzinga · April 1, 2025
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · March 28, 2025
Via Benzinga · March 28, 2025
Via Benzinga · March 27, 2025
Via Benzinga · March 25, 2025